Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Q3 2025
Arcturus Therapeutics Holdings (ARCT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Arcturus Therapeutics Holdings (ARCT) reported revenue of $17.2M for the third quarter 2025 (Q3 2025), -59% from a year earlier and -39% from the quarter before. Operating margin was -96.3%, net loss $13.4M (78.4% of revenue).
Arcturus Therapeutics Holdings, Q3 2025: revenue $17.2M (-59% year over year), operating margin -96.3%, net loss $13.4M, operating cash flow −$17.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.2M | -39% | -59% |
| Operating profit | −$16.5M | — | — |
| Net earnings | −$13.4M | — | — |
| Operating cash flow | −$17.2M | — | — |
What changed
Revenue was $17.2M in Q3 2025, down 59% year over year and down 39% from the previous quarter. Collaboration Revenue was the largest line at 83% of revenue. Collaboration Revenue lost $24.7M year over year (down 64%), 101% of the total change.
Operating costs exceeded revenue by $16.5M, an operating margin of -96.3%. Total costs fell 36% while revenue fell 59%. The quarter ended with a net loss of $13.4M, wider than the previous quarter's $9.2M loss. Non-operating items added $3.1M, -23% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$17.2M. Non-cash charges added back $800K of depreciation and amortization and $5.7M of share-based compensation. Working capital and other items used $10.2M. Capital expenditures of $181K exceeded it, leaving free cash flow of −$17.3M.
Questions
What was Arcturus Therapeutics Holdings' revenue in the third quarter 2025?
Arcturus Therapeutics Holdings (ARCT) reported revenue of $17.2M for the third quarter 2025 (Q3 2025), -59% from a year earlier and -39% from the quarter before.
Was Arcturus Therapeutics Holdings profitable in the third quarter 2025?
Operating loss was $16.5M (-96.3% of revenue) and net loss $13.4M.